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Earlier studies of psoriatic and normal primary ker-
atinocytes treated with phorbol 12-myristate-1-acetate
identified two low-molecular-weight proteins, termed
phorbolin-1 (20 kDa; pI 6.6) and phorbolin-2
(17.6 kDa; pI 6.5). As a first step towards elucidating
the role of these proteins in psoriasis, we report here
the molecular cloning and chromosomal mapping of
phorbolin-1 and a related cDNA that codes for a
protein exhibiting a similar amino acid sequence. The
phorbolins were mapped to position 22q13 immedi-
ately centromeric to the c-sis proto-oncogene. Transi-
ent expression of the phorbolin-1 cDNA in COS
cells and by in vitro transcription/translation, yielded
polypeptides that comigrated with phorbolins-1 and -
Psoriasis is a hyperproliferative inflammatory disease thataffects about 2% of the population in northern Europeand Scandinavia. The disease is histopathologically char-acterized by hyperproliferation and aberrant differenti-ation of the epidermal keratinocytes and by invasion of
neutrophils and T lymphocytes (Wright and Camplejohn, 1985).
Currently, relatively little is known about the molecular mechanisms
underlying the disease, although numerous studies have been
devoted to the analysis of gene products known to be involved in
proliferation and immune activation. These include: cytokines,
growth factors, adhesion molecules, proteases, proto-oncogenes, as
well as other proteins of yet unknown functions (Elder et al, 1990;
Madsen et al, 1991, 1992; Wiedow et al, 1993; Barker, 1994, 1995;
Valdimarsson et al, 1995; Christophers, 1996; Norris et al, 1997).
Recently, we presented evidence suggesting that the protein kinase
C (PKC) signaling pathway may be altered in psoriasis, as treatment
of normal keratinocytes with phorbol 12-myristate 13-acetate
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2. Comparative sequence analysis revealed 22% overall
identity and a similarity of 44% of the phorbolins to
apobec-1, the catalytic subunit of the mammalian
apolipoprotein B mRNA editing enzyme; however,
recombinant-expressed phorbolin-1 exhibited no
cytidine deaminase activity, using either a monomeric
nucleoside or apolipoprotein B cRNA as substrate,
and failed to bind an AU-rich RNA template. Whereas
the precise function of the phorbolins remains to be
elucidated, the current data suggest that it is unlikely
to include a role in the post-transcriptional modifica-
tion of RNA in a manner analogous to that described
for apobec-1. Key words: cDNA cloning/mRNA editing.
J Invest Dermatol 113:162–169, 1999
(PMA), an activator of PKC, leads to the overexpression of proteins,
including phorbolins-1 and -2, that are also highly expressed in
psoriatic lesions (Rasmussen and Celis, 1993). The effect was not
elicited by other effectors such as second messengers (Bt2cAMP,
Bt2cGMP) and cytokines [basic fibroblast growth factor, trans-
forming growth factor-α, tumor necrosis factors-α and -β, interleu-
kin (IL) -1α, IL-1β, IL-2, IL-3, IL-6, IL-7, IL-8, and interferons
α and γ], but was partly mimicked by fetal bovine serum, which
is known to induce abnormal differentiation, a characteristic of
psoriatic keratinocytes (Rasmussen and Celis, 1993). Evidence for
altered levels of PKC in psoriasis has been reported by several
laboratories (Horn et al, 1987; Fisher et al, 1990, 1993; Venneker
et al, 1994), and it has been suggested that PKC inhibitors may
have a therapeutic value (Gupta et al, 1988; Hegemann et al,
1992a, b).
In this study, we report the cloning and expression of phorbolin-
1 and of a homologous cDNA called phorbolin-1-related cDNA.
Comparative cDNA sequence analysis revealed 20% identity
between the phorbolins-1 and -2 and apobec-1, the catalytic
subunit of the mammalian apolipoprotein B mRNA editing enzyme
complex (Teng et al, 1993). In humans, apobec-1 is expressed in
the small intestine, where it functions in the post-transcriptional
deamination of C to U of apolipoprotein B mRNA (Teng et al,
1993), a process referred to as RNA editing (Ashkenas, 1997). The
conversion of a CAA codon (encoding glutamine) to a UAA stop
codon in the primary nuclear apolipoprotein B transcript results in
the tissue-specific production of apoB48 (Teng et al, 1993). One
of the regions homologous between phorbolin-1 and apobec-1
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was one that encompassed the zinc-coordinating residues corres-
ponding to the active site of known cytidine deaminases
(Bhattacharya et al, 1994). This apparent similarity in primary
sequences led us to determine directly whether phorbolin-1 exhibits
activity as a cytidine deaminase. Our results show that, despite the
apparent homology, the phorbolin-1 protein demonstrates no
detectable cytidine deaminase activity when assayed either on a
monomeric nucleoside substrate or a synthetic apoB RNA template.
Accordingly, the precise function of the phorbolins remains elusive.
The possibility, however, that these proteins may play a part in the
editing of other mRNA through an as yet unknown mechanism
cannot be excluded at present.
MATERIALS AND METHODS
Normal primary human keratinocytes Strips of normal skin were
washed three times in Hank’s buffered saline (HBSS) and placed in 0.25%
trypsin in HBSS at 4°C for at least 24 h. Following incubation, the strips
were washed three times in serum-free keratinocyte medium (Gibco,
Cleveland, OH) containing antibiotics (100 U penicillin per ml; 50 µg
streptomycin per ml; Biochrom KG, Germany; 5 ng epidermal growth
factor per ml and 50 µg bovine pituitary extract per ml). The epidermis
was then detached from the dermis and resuspended in the same medium.
Keratinocytes were detached by vigorous shaking, washed two to three
times in serum-free keratinocyte medium and plated in 35 mm culture
dishes (coated with human dermal extract) that contained 3 ml of complete
serum-free keratinocyte medium. Keratinocytes were fed with fresh
medium every day and loosely attached cells were eliminated by pipetting
the medium up and down with the aid of an automatic pipette. Cell were
labeled for 20 h in serum-free keratinocyte medium lacking methionine
and containing 50 µCi of [35S]methionine (SJ 204 Amersham, Uppsala,
Sweden) per 0.1 ml of medium. At the end of the labeling period the cells
were resuspended in lysis solution (Bravo and Celis, 1982).
Preparation of human dermal extracts Strips of normal skin washed
in HBSS were placed in HBSS containing 1 M NaCl for 72 h at 4°C.
The epidermis was then peeled off and the dermis washed twice in HBSS.
Thereafter, the dermis was homogenized in the same buffer and the soluble
extract was recovered by centrifugation. The extract was then dialyzed
against HBSS, filter sterilized, and stored at 4°C. Petri dishes were coated
with the extract overnight at 4°C (20 µg per ml). The extract was then
aspirated and the plates were kept at 4°C until use.
Production of antibodies in rabbits A polymerase chain reaction
fragment encoding the 103 C-terminal amino acids of phorbolin-1 was
cloned into pT7-PL vector (Christensen et al, 1991) and expressed as a
hexaHis fusion protein in Escherichia coli BL21(DE3) by isopropyl-β-D-
thiogalactopyranoside induction. The protein was purified under denaturing
conditions on a Ni21 column (Hochuli et al, 1987), and thereafter
exchanged by gel filtration into 150 mM KCl and 20 mM HEPES pH 7.4.
The purified protein was mixed with Freund’s complete adjuvant and
injected into a rabbit, followed by a boost injection using incomplete
Freund’s 4 wk later. Blood was collected after additional 8 d and the
specificity of the antibody was determined by two-dimensional (2D)
immunoblotting of PMA-treated keratinocytes. The serum was precipitated
with an equal volume of saturated (NH4)2SO4 and the resulting precipitate
was dialyzed against HBSS. Aliquots were kept frozen at –80°C.
In vitro transcription/translation The TNT Coupled Reticulocyte
Lysate system from Promega (Madison, WI) was used according to
the manufacturer’s description. The phorbolin-1 and phorbolin-1-related
cDNAs were inserted into pBluescript-SK (derived from the λZAP library)
and expressed using T3 polymerase. The phorbolin-1-related cDNA was
transcribed from position 181. Following translation in the presence of
[35S]methionine (Madsen et al, 1995), the lysates were mixed with an
equal volume of lysis solution and subjected to 2D polyacrylamide gel
electrophoresis (PAGE), described below (Bravo and Celis, 1982).
RNA editing, RNA binding, and PHYLIP analysis A recombinant
form of apobec-1, the catalytic subunit of the mammalian apolipoproteinB
mRNA editing enzyme, was expressed as a glutathione S-transferase (GST)-
fusion protein as previously described (Anant et al, 1995; MacGinnitie et al,
1995). Recombinant apobec-1 as well as in vitro transcription/translation
synthesized apobec-1 was used in an in vitro editing assay with a synthetic
apolipoprotein B RNA template containing 470 nt spanning the edited
cytidine at position 6666 in the apolipoproteinB cDNA (Anant et al, 1995;
MacGinnitie et al, 1995). Twenty femtomol of RNA was incubated with
500 ng of GST-apobec-1 in the presence of 10 µg of chicken intestinal
S100 extracts (an obligate source of auxiliary factors for in vitro RNA
editing) and the reaction allowed to proceed for 2 h at 30°C. In a parallel
set of incubations, 2 µl of the in vitro transcription/translation products of
phorbolin-1 was used along with 10 µg chicken S100 extract. The reaction
products were used to determine the extent to which the cytidine at
position 6666 is converted to uridine by means of a primer extension/
dideoxy chain termination reaction. Specifically, a 35-mer oligonucleotide
complementary to the sense strand of apolipoproteinB mRNA in the
region starting 8 nt downstream of the edited base, was annealed and
allowed to extend with reverse transcriptase in the presence of µM dATP,
dCTP, dTTP, and high concentrations of ddGTP (500 µM) as a chain
terminator. If the cytidine at position 6666 is unedited, the reaction
terminates at this position, giving an extension product of 43 nt. If nt 6666
is edited to a uridine, the extension continues to the next upstream
cytidine, located at position 6655, which results in an extension product
of 54 nt. The extended products are resolved on an 8% urea–polyacryl-
amide gel.
Ultraviolet cross-linking was conducted using a [32P]-labeled RNA
template containing 105 nt of rat apolipoproteinB mRNA spanning the
edited base (Giannoni et al, 1994; MacGinnitie et al, 1995). Approximately
50 000 cpm was incubated with recombinant GST-apobec-1 or GST-
phorbolin-1-related protein for 20 min at room temperature and the
products treated with RNase T1 and heparin prior to ultraviolet cross-
linking in a Strategene cross-linker set at 250 mJ per cm2. The reaction
products were then subjected to reducing 10% sodium dodecyl sulfate
(SDS)–PAGE and fluorography.
Phylogenetic analysis was performed by PHYLIP ver. 3.572c using the
active site of cytosine nucleotide and nucleoside deaminases and the RNA
editing enzymes (Felsenstein, 1988) The distance matrix between the
various proteins was calculated by PROTDIST program using the Dayhoff
PAM matrix method. The matrix was used to generate a tree by the
KITCH program using the Fitch-Margoliash method and the tree plotted
using the Drawgram program.
2D PAGE SDS–PAGE, 15% running gel; 5% stacking gel) was carried
out essentially as described by Laemmli (1970). 2D gel electrophoresis
(isoelectric focusing, nonequilibrium pH gradient electrophoresis)
(O’Farrell, 1975) was carried out as described by Celis et al (1994b). In
short, the first dimension was performed either as isoelectric focusing (18 h
at 400 V) in 125 3 2 mm 4% wt/vol polyacrylamide gels containing 2%
wt/vol carrier ampholytes (1.6% pH 5–7, Serva, Heidelberg, Germany;
0.4% pH 3.5–10, Pharmacia Biosystems AS, Uppsala, Sweden). First-
dimensional gels placed in 3 cm Petri dishes were equilibrated (3 min at
room temperature) in 3.5 ml of equilibration solution (0.06 M Tris–HCl,
pH 6.8, 2% SDS, 100 mM dithiothreitol, and 10% glycerol) (O’Farrell,
1975). Gels were then stored at –20°C until use (usually 1–2 wk). First-
dimensional gels were applied to the second dimension with the aid of
agarose solution (0.06 M Tris–HCl, pH 6.8, 2% SDS, 100 mM dithiothreitol,
10% glycerol, 1% agarose, and 0.002% Bromophenol Blue) (O’Farrell,
1975). Gels were run at room temperature at 10 mA for 4 h and at 3 mA
overnight. Solutions and procedures used to run 2D gels in our laboratory
are described in detail at: http://biobase.dk/cgi-bin/celis
Microsequencing Protein spots from several Coomassie-stained, dried
2D gels were cut and combined and concentrated by elution-concentration
gel electrophoresis (Rasmussen et al, 1991; Vanderkerckhove and
Rasmussen, 1994). Polyvinylidene difluoride bound proteins were visual-
ized by staining with 0.1% Amido Black in 45.5% methanol, 9% acetic
acid and destained in water. The wet protein bands were cut out and
placed in 500 µl 0.2% polyvinylpyrolidone in water for 15 min in order
to quench remaining protein binding sites on the membrane. After washing
the membrane was placed in 100 µl digestion buffer containing 1 µg
porcine trypsin. The digestion proceeded for 4 h at 37°C. The tryptic
peptides were released from the membrane by adding 10 µl trifluoracetic
acid (TFA) and separated by reversed-phase high-performance liquid
chromatography on a C18 C4 reversed-phase column (0.46 3 25 cm;
Vydac Separations Group). The major peptides were further dried in a
SpeedVac (Savant) concentrator and stored at –20°C prior to sequence
analysis. Peptides were selected for amino acid sequence, redissolved in
30 µl of 0.1% TFA/30% acetonitrile before loading on a precycled
Polybrene-coated glass filter. The sequence analysis was carried out with
pulse-liquid sequencer (model 477A, Applied Biosystems, Forster City, CA)
and run with the sequencing program recommended by the manufacturer.
2D gel immunoblotting 2D gels for immunoblotting were placed for
5 min in TGM (Tris, glycine, methanol) prior to transfer (24 h at 130 mA)
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(Towbin et al, 1979; Celis et al, 1994a). Following protein transfer
(total cellular extracts from keratinocytes mixed with small amounts of
[35S]methionine-labeled extracts) on to nitrocellulose, the sheet or strip
was dried and exposed to an X-ray film. The amount of keratinocyte cell
extract applied to the gels was carefully calibrated to obtain the maximum
amount of protein transferred without affecting the quality of the 2D gels.
Dry sheets could be kept for extended periods of time (up to 3 mo) without
significant change in the reactivity of the proteins. For immunodetection of
the antigen the following procedure was used: nitrocellulose strips or sheets
were incubated for 16 h at room temperature in HBSS containing 1.5%
bovine hemoglobin (Sigma, St. Louis, MO, type II). The blots were then
incubated at room temperature for 2 h with HBSS containing 2%
hemoglobin and a 1:100 of the first antibody. After three washes with
HBSS (3 3 30 min), the blot was incubated with peroxidase-labeled
second antibody (Dakopatts AS, Denmark; 1 : 100 dilution) for 2 h. It
was then washed three times (3 3 30 min) with HBSS and finally
developed in enhanced chemiluminescence solution (Amersham, Uppsala,
Sweden), and exposed to X-ray film.
Chromosome localization Fluorescence in situ hybridization mapping
was carried out by nick labeling of the phorbolin-1 cDNA in the presence
of bio-dUTP followed by hybridization to human metaphase chromosomes.
Metaphases were examined in Zeiss Periplan epifluorescence microscope
(Tommerup and Vissing, 1995). The phorbolin cDNA probes were
hybridized to high-density cosmid filters prepared from the libraries and a
unique set of 26 positive cosmid clones was identified. Random hexamer
labeled HindIII digested cosmid DNA was denatured in the presence of
2.5 mg sonicated human placental DNA per ml (Sigma). This was
hybridized overnight at 65°C to a single high-density gridded chromosome
22 YAC filter (Collins et al, 1995). The filter was washed with 0.5 3
sodium citrate/chloride buffer at 65°C for 1 h and visualized by autoradio-
graphy. The cosmid probe was positioned relative to markers in the
chromosome 22 YAC map by YAC marker content (Collins et al, 1995).
Purification of RNA, preparation, and screening of cDNA
libraries Total RNA was purified from trypsin detached psoriatic epi-
dermis by homogenization in a 4 M solution of guanidinium thiocyanate
and 0.1 M 2-mercaptoethanol, followed by sedimentation through cesium
chloride (Chirgwin et al, 1979). Messenger RNA was isolated using a
oligo-dT column from Stratagene (La Jolla, CA). The cDNA library was
constructed by priming mRNA with (dT)15 containing XhoI and SacI site
at the 59 end. The cDNA was ligated into λ Uni-ZAP-XR cut with XhoI
and EcoRI (Gubler and Hoffman, 1983). The amplified library was plated
on 22 3 22 cm plates containing 1.5 3 105 plaque-forming units, and
overlaid with nylon filters (Hybond-N, Amersham). The DNA was
covalently linked to the filters by ultraviolet light. Following 59 labeling
the degenerated oligonucleotides were used to screen replica filters using
a modification of the tetramethylammonium chloride salt method (Honore´
and Madsen, 1997). The filters were sealed in plastic bags, and autoradio-
graphy was done with Kodak X-ray films. Positive clones were purified
by repeated platings and rescued in pBluescript. The purified clones were
sequenced by the dideoxy method (Sanger et al, 1977).
RESULTS
Microsequencing, molecular cloning, and expression of
phorbolin-1 Coommassie brilliant blue-stained phorbolin-1
recovered from several isoelectric focusing 2D gels from psoriatic
keratinocytes were pooled, and tryptic peptides were sequenced
(Fig 1). A cDNA that coded for phorbolin-1 was cloned by
screening a λZAP psoriatic epidermis cDNA expression library
using degenerate oligodeoxyribonucleotides back-translated from
one of the peptide sequences (IYDYDPLYK). Several positive
cDNA clones were isolated and sequenced, but only the deduced
amino acid sequence from clone 4359 contained all of the tryptic
peptides that were microsequenced (Fig 1). As shown in Fig 1,
the open-reading frame of clone 4359 encodes a protein comprising
199 amino acids, with a molecular mass of 23.012 kDa and a
calculated pI of 6.83. These values are very close to those recorded
for phorbolin-1 in the 2D PAGE database of keratinocyte proteins
(20.0 kDa; pI 6.6) (Celis et al, 1996). (The 2D PAGE human
keratinocyte protein database is also available on the internet:
http//biobase.dk/cgi-bin/celis) The 39-UTR region of clone 4359
contains an ALU repeat sequence spanning positions 841–1130
(Fig 1). To substantiate further that clone 4359 codes for phorbolin-
1, we compared the 2D PAGE profile of clone 4359 overexpressed
Figure 1. Nucleotide and deduced amino acid sequence of the
phorbolin-1 cDNA. Nucleotide and corresponding amino acid sequence
of the cDNA clone encoding for isoelectric focusing SSP 2116 (Rasmussen
and Celis, 1993). The cDNA, which contains 1348 bp, codes for a protein
having 199 amino acids starting at nucleotide position 76 and ending with
a termination codon at position 675. Potential AUG start codons are
marked with asterisks, and partial peptide sequences obtained by
microsequencing are underlined. Accession number U03891.
in COS-1 cells with that of the native protein overexpressed in
PMA-treated keratinocytes (Fig 2A, B). By superimposing the
autoradiograms it was possible to show that the protein overex-
pressed by COS-1 cells transfected with clone 4359 comigrated
with phorbolin-1 expressed by PMA-treated keratinocytes (Fig 2A,
B). Taken together, the results provide strong evidence that clone
4359 codes for phorbolin-1.
COS-1 cells transfected with clone 4359 express, in addition to
phorbolin-1, a low-molecular-weight protein that comigrates with
phorbolin-2 (Fig 2A, B). Both this protein and phorbolin-1 reacted
with a rabbit polyclonal antiserum directed against the 103 hexaHis-
tagged C-terminal amino acids of clone 4359 expressed in bacteria
(Fig 2C), suggesting that the low-molecular-weight protein is
derived from clone 4359. Non-transfected COS-1 cells did not
react with the anti-serum (not shown). The increased sensitivity of
the enhanced chemiluminescence detection procedure revealed, in
addition, acidic variants of both phorbolin proteins (Fig 2D). The
nature of the acidic variants is at present not known. 2D PAGE
analysis of proteins expressed by clone 4359 using the TNT-
coupled in vitro transcription/translation system yielded essentially
the same results (Fig 2D) as those observed in the COS-1 transfected
cells (Fig 2A, C). At present, we do not know whether phorbolin-
2 is derived as a result of differential AUG codon usage or of
proteolysis of phorbolin-1. Analysis of the phorbolin-1 cDNA
sequence revealed three AUG codons located downstream of an
in-frame stop codon at position 20 that could potentially be used
as translational initiation codons (Fig 1). Differential usage of AUG
codons may explain the different ratios between phorbolin-1 and
2 observed in Fig 2(A, C, D), as ribosome scanning of the 59
mRNA may select AUG codons with different probabilities in the
various expression systems analyzed.
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Figure 2. Expression of clone 4359. (A) 2D PAGE autoradiogram of
[35S]methionine-labeled polypeptides from COS-1 cells transfected with
clone 4359, inserted into the pMT21 eukaryotic expression vector.
Overexpressed proteins are indicated by arrows, these proteins are not
detected in non-transfected COS-1 cells (not shown). (B) 2D PAGE
autoradiogram of [35S]methionine-labeled polypeptides from primary
human keratinocytes treated for 20 h with PMA (100 ng per ml), 5 d after
plating. PMA-induced proteins are indicated by name. (C) 2D immunoblot
of COS-1 cells transfected with clone 4359, using a rabbit anti-serum
directed against the C-terminal of clone 4359. (D) 2D PAGE autoradiogram
of clone 4359 assayed in the in vitro transcription/translation system. (E)
2D PAGE autoradiogram of the phorbolin-1-related cDNA expressed by
the in vitro transcription/translation system. Overexpressed proteins in C–
E are indicated by arrows, acidic variants are indicated by arrowheads.
Asterisks in D and E indicates a common translational product that is not
related to the expressed cDNA, as this protein also is detected when
expressing unrelated cDNA (Madsen et al, 1995).
Phorbolin-1-related cDNA Sequence analysis of several clones
hybridizing to the fully degenerate oligodeoxyribonucleotide probes
revealed cDNA clones closely related to the phorbolin-1 cDNA.
The deduced amino acid sequence exhibited an overall identity of
Figure 3. Alignment of the phorbolins and apobec-1. Identical
residues are highlighted in a black background whereas similar residues are
in gray. The region containing the active site and zinc coordinating spans
residues 61–96 in the apobec-1 amino acid sequence.
89% to the phorbolin-1 amino acid sequence, with the major
differences found near the amino terminus (Fig 3). The mRNA
for this cDNA has many AUG codons upstream of an in-frame
stop codon at position 372 and several potential start codons
downstream of this stop codon (Fig 4). Analysis of the in vitro
transcription/translation products from the phorbolin-1-related
cDNA clone B, which starts at position 181 (and therefore has no
interference from the AUG codons upstream of this position)
revealed two proteins having pI of approximately 5 and apparent
molecular masses of 28 and 18 kDa, respectively. From the
differences in molecular weights and pI, we conclude that the
phorbolin-1-related cDNA encodes proteins that are unrelated to
phorbolin-1 and -2 (Fig 2F). Sequence analysis of seven independ-
ent phorbolin-1-related cDNA clones revealed sequence variation
at position 673, which in turn creates further uORF (Fig 4). In
three of the clones there is a T at position 673, creating an in-
frame UGA stop codon, whereas in four clones there is a C at that
position, thereby coding for an arginine (CGA) at position 63
(Fig 4). Sequence analysis of the corresponding genomic positions
of two independent cosmid clones showed that a C is indeed
present. Further analysis of more alleles, however, is necessary in
order to establish whether genomic variation exists at this position.
Protein alignment and functional assay The predicted amino
acid sequence derived from the phorbolin cDNA clones was used
to search the GenBank, using the Blast Search program to identify
homologous sequences. The search revealed that phorbolin-1 had
a significant homology to apobec-1, with an overall identity of
20% and a similarity of 44%, requiring six gaps to be inserted to
make them align (Fig 3). In particular, the homologous regions in
the phorbolins include the sequence His-(Ala)-Glu-X-X-Phe-X-
(19)-Phe-(Ile)-Ser-Trp-Ser-Pro-Cys-X-(4)-Cys, which are amino
acids 70–106 in the phorbolins (Fig 3). In apobec-1, this region
has been shown to encompass the active site of the enzyme and
contains the zinc coordinating residues (one histidine and two
cystine residues) required for cytidine deaminase activity, as well as
the conserved glutamate residue that functions as a proton donor
(Anant et al, 1995; MacGinnitie et al, 1995). In addition, the proline
(at position 92 in apobec-1) and the two phenylalanine residues
(at positions 66 and 87 in apobec-1) are conserved in the phorbolins.
166 MADSEN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Figure 4. Nucleotide and deduced amino acid sequence of the
phorbolin-1-related cDNA. Nucleotide and corresponding amino acid
sequence of the phorbolin-1-related cDNA clone. The cDNA, which
contains 1526 bp, codes for a protein having 235 amino acids starting at
nucleotide position 486 and ending with a termination codon at position
1191. The in-frame upstream stop codon at position 372 is underlined and
in italics. ORF start codons are numbered with their corresponding
nucleotide positions and are marked with asterisks. uORF AUG codons
are underlined. Accession number U61084.
All three of these residues were shown to be necessary for apoB
RNA editing activity and were, in addition, required for RNA-
binding activity of recombinant apobec-1 (Anant et al, 1995;
MacGinnitie et al, 1995; Navaratnam et al, 1995).
The similarity of the phorbolins to apobec-1 was further substanti-
ated by a PHYLIP analysis, using the distance analysis program
PROTDIST. The analysis of the active site of the phorbolins with
that of apobec-1 and with other cytosine nucleoside and cytosine
nucleotide deaminases also suggested that the phorbolins form a
separate cluster with the apobec-1 sequences that is distinct from
the other deaminases (Fig 5). Previous analyses have shown that
the RNA-editing enzymes form a separate subgroup, and association
of the phorbolins with this group suggests that the phorbolins may
have evolved in order to edit a currently unknown RNA. This
apparent homology between apobec-1 and the phorbolins raised
the possibility that the phorbolins may compete or interact with
apobec-1 in the editing of apoB RNA (Fig 6). Accordingly, we
used preparations of phorbolin-1, synthesized in the TNT system,
in an in vitro apoB RNA editing reaction, followed by primer
extension analysis and SDS–PAGE of the edited products. Several
controls were included to validate the use of this material (Fig 6).
A representative assay is shown in Fig 6, which illustrates that
Figure 5. Phylogenetic analysis of the active sites of cytidine
deaminases and the Phorbolin-1. The active site domain containing
the zinc coordinating and proton donor residues were aligned as previously
described based on the crystal structure of the E. coli cytidine deaminase
(Betts et al, 1994; Anant et al, 1997). The distance matrix between the
various cytidine deaminases was calculated using the PROTDIST program
and used to generate a tree by the KITSCH program.
Figure 6. In vitro RNA editing assay. A 470 nucleotide apoB RNA
was incubated with 10 µg of chicken enterocyte S-100 extract and in vitro
transcribed/translated proteins, followed by primer extension using a
radiolabeled primer (Anant et al, 1995). Lane 1, in vitro transcription/
translation extract without plasmid DNA; lane 2, in vitro synthesized apobec-
1; lane 3, in vitro synthesized phorbolin-1; lane 4, in vitro synthesized
phorbolin-1 plus apobec-1; lane 5, in vitro synthesized PA-FABP (Madsen
et al, 1992) plus apobec-1; lane 6, bacterially expressed and purified GST/
apobec-1; lane 7, negative control, apoB RNA alone. This is a representative
of two independent assays.
phorbolin-1 demonstrates neither complementation of apobec-1
(lane 3) nor competition with apobec-1 in a standardized in vitro
apoB RNA editing assay (lane 4). In addition, as alluded to earlier,
previous experiments demonstrated that recombinant apobec-1 has
authentic cytidine deaminase activity on a monomeric nucleoside
substrate (MacGinnitie et al, 1995). Despite the observation that
phorbolins contain the conserved catalytic domain found in other
cytidine deaminases, direct experimental examination revealed no
detectable cytidine deaminase activity using bacterially expressed
phorbolin-1-related protein (data not shown). It remains formally
possible that, as the assay used a chimeric GST fusion protein,
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Figure 7. Phorbolin-1-related does not bind to an apoB RNA
template. Ultraviolet cross-linking was performed using a radiolabeled
105 nucleotide rat apoB RNA template in the presence of 0.25 or 1 µg
of recombinant GST/APOBEC-1 or GST/phorbolin-1. After digestion
with RNAse T1, the samples were size fractionated in to a 10% SDS–
PAGE gel, dried, and autoradiographed. Molecular weight markers are
shown to the left. This is a representative of two independent assays.
conformational changes resulting from the GST moiety interfered
with any potential cytidine deaminase activity. Although we have
no direct evidence for this, further experiments will need to be
conducted using cleaved protein. Another important activity of
apobec-1 concerns its ability to bind RNA substrates, particularly
those rich in A 1 U sequences (Anant et al, 1995). We examined
the ability of a GST-phorbolin-1-related fusion protein to bind to
a candidate AU-rich template, namely, a [32P]-labeled rat apoB
RNA sequence made up of 105 nucleotides that flanked the edited
base. The protein–RNA complexes were ultraviolet cross-linked
and visualized by SDS–PAGE. As shown in Fig 7, there was no
evidence for RNA binding of either 0.25 or 1 µg of GST-
phorbolin-1-related protein, under conditions in which the same
quantities of GST-apobec-1 protein demonstrated a distinct protein–
RNA complex. These findings suggest that the phorbolin-1-related
protein does not function as an apoB RNA binding protein,
although it should be emphasized that the possibility of its binding
to other RNA templates cannot be excluded.
Taken together, the results demonstrate that the phorbolins do
not manifest any of the functional properties previously ascribed
to apobec-1 (Anant et al, 1995; MacGinnitie et al, 1995). Con-
sequently, it must be concluded that, despite the apparent similarity
of the primary sequences, no functional significance can be ascribed
at present to the expression of phorbolins that in any way duplicates
or complements the activity of apobec-1.
Chromosome mapping Using the fluorescence in situ hybrid-
ization technique (Tommerup and Vissing, 1995), we mapped the
phorbolin genes to chromosome 22q (not shown). To refine the
chromosomal localization of the phorbolin genes, we used two
chromosome 22-specific cosmid libraries (LL22NC01 and
LL22NC03) constructed at the Lawrence Livermore National
Laboratory, CA, and permanently arranged in microtiter-format
(Xie et al, 1993). The full list of positive cosmids is available from
the authors upon request. The phorbolin cDNA probes were
hybridized to high-density cosmid filters prepared from the libraries,
and a unique set of 26 positive cosmid clones was identified. None
of the positive cosmids had been previously recognized upon
screening the libraries with a large number of various genomic and
cDNA probes specific for human chromosome 22. The phorbolin-
1-related probe identified five cosmids, none of which were
identified by the phorbolin-1 cDNA probe. These results indicate
that the phorbolins genes are located close to each other in a
cluster. The exact position of the phorbolin gene cluster on
chromosome 22 was finally resolved by the hybridization of one
of the phorbolin-positive cosmids to the high-density filter that
contained YAC clones arranged in a contig spanning the entire
long arm of chromosome 22 (Collins et al, 1995). These results
show that the phorbolin genes are localized close to the markers
D22S292E and D22S314E, which are positioned at 22q13 immedi-
ately centromeric to the PDGFB gene (c-sis proto-oncogene)
(Collins et al, 1995).
DISCUSSION
There are at least two main features that point towards phorbolins-
1 and -2 as putative players in the pathophysiology of psoriasis.
First, these proteins are highly upregulated in the psoriatic plaques
(Rasmussen and Celis, 1993), and second, their synthesis is modu-
lated by only a few effectors (Rasmussen and Celis, 1993) that, so
far, include PMA, an activator of PKC, and fetal bovine serum,
which is known to induce abnormal keratinocyte differentiation,
a characteristic of psoriasis (Rasmussen and Celis, 1993). Second
messengers (Bt2cAMP, Bt2cGMP) as well as other effectors (basic
fibroblast growth factor, transforming growth factor-α, tumor
necrosis factors-α and -β, IL-1α and IL-1β, IL-2, IL-3, IL-6, IL-7,
IL-8, and interferons α and γ) tested so far have failed to deregulate
the synthesis of these proteins, lending support to the contention
that the abnormal expression of the phorbolins in psoriasis may be
linked to an altered PKC signal transduction pathway (Nishizuka,
1992). This postulate is in line with studies from other laboratories
that have shown that psoriatic lesions contain elevated levels of
phosphoinositide phospholipase C activity and 1,2-diacylglycerol
as compared with normal skin (Fisher et al, 1990), and that
glycosylphosphatidylinositol-anchored membrane proteins are con-
stitutively downregulated in psoriatic skin, perhaps as a result of
the increased phosphoinositide phospholipase C activity (Venneker
et al, 1994). Furthermore, there is evidence that calcium-dependent
PKC activity is lower in psoriatic lesions than in normal skin and
that is most likely due to a downregulation of the PKC-βII variant
(Horn et al, 1987). These observations have led to the notion that
the PKC pathway is altered in psoriatic skin, and it has been
suggested that PKC inhibitors may have therapeutic value (Gupta
et al, 1988; Hegemann et al, 1992a,b).
The potential differential usage of AUG codons by the phorbolins
is interesting as in some cases this process has been shown to yield
products with different functional characteristics (Nishizuka, 1992;
Geballe and Morris, 1994). For example, a single transcript from
the C/EBPβ gene, encodes the liver-enriched transcriptional activ-
ator LAP and the alternative product LIP, which initiates at the
third AUG codon and functions as a transcriptional repressor. The
relative abundance of the two forms determines the transcriptional
effect, which, in turn, is developmentally regulated (Descombes
and Schibler, 1991). In addition, both the selection of AUG start
codons and the tissue-specific expression of genes have been shown
to be regulated by uORF. Thus, the presence of a small uORF in
the C/EBPα mRNA has been shown to play a crucial part in the
leaky scanning mechanism of ribosomes causing a fraction of them
to ignore the first C/EBPα codon (Calkhoven et al, 1994).
Furthermore, the tissue-specific expression of the retinoic receptor-
β2 (RAR β2) gene in mouse embryos is regulated at the translational
level by short uORF and there is experimental evidence indicating
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that the uORF4 amino acid coding sequence is important for the
inhibitory effect on the translation of the downstream major ORF
(Reynolds et al, 1996). Further analysis of psoriatic skin is necessary
to establish whether the phorbolin cDNAs are translated using
differential start codons.
The presence of multiple uORF in the phorbolin-1-related
cDNA reveals a complex mRNA structure that may be under
translational control, both with respect to translational activity and
to selection of AUG start codons. Furthermore, the presence of an
in-frame stop codon at position 673 raises the possibility that the
mRNA may be edited, thereby allowing the synthesis of N-
terminal truncated variants that may have altered biochemical
activities relative to variants translated from more upstream AUG
start codons. Phorbolin-1-related mRNAs having a stop codon at
position 673 will most likely be subject to translational regulation,
as this mRNA has 18 uORF AUG codons that will probably
suppress translation from the AUG codon at position 735. The
role of the uORF as well as the potential editing of the phorbolin-
1-related mRNA will require additional work and will be the
subject of future studies. It should be noted that the presence of
uORF is strongly biased towards products of proto-oncogenes,
transcriptional factors, genes encoding growth factors, and cell-
surface receptors (Kozak, 1989; Geballe and Morris, 1994), lending
weight to the notion that the phorbolins may be involved in an
important regulatory process.
Despite the apparent sequence similarity to apobec-1, particularly
within the region encompassing the catalytic domain, including
several residues demonstrated to be required for enzymatic activity
as well as RNA binding, no functional activity of phorbolins could
be demonstrated, at least with the available assays. It remains a
possibility that the phorbolins could function in the context of
other RNA targets, such as those suggested for neurofibromatosis
(NF) 1, but this remains purely speculative at present. To date, two
other transcripts have been shown to undergo base modification,
possibly affecting tumor suppressor activity (Ashkenas, 1997). These
include the NF type I gene product, where a cytidine is converted
into uridine (Skuse et al, 1996; Cappione et al, 1997), and the
Wilms’ tumor susceptibility (WT1) gene product, where a uridine
is converted into cytidine (Sharma et al, 1994). NF1 editing is
believed to occur in a fashion similar to that observed in apoB
(Skuse et al, 1996; Cappione et al, 1997). Interestingly, the level of
the NF1 protein is reduced in psoriatic skin, as detected by indirect
immunofluorescence, and as a result, it has been suggested that this
protein may play a part in the disease (Peltonen et al, 1995). Studies
are currently underway to determine: (i) if abnormal levels of
edited NF1 transcript are present in psoriatic skin, and (ii) the
potential involvement of the phorbolins in this process.
Note added in proof: Recently two genomic clones from
chromosome 22 have been sequenced and been found to contain
sequences homologous to the phorbolin cDNA described here
(acc. no. AL022318 and AL031846).
We thank Else Walbum, Jette B. Lauridsen, Bodil Basse, and Gitte Ratz for
expert technical assistance and Pablo Celis for doing the artwork. The work was
supported by grants from the Danish Medical Research Council, the Danish
Biotechnology and Development Programme, the Danish Research Center for
Growth and Regeneration, the Danish Cancer Society, the Velux Fund, NOVO
Nordisk, the Carlsberg Foundation and the Danish Foundation for the Advancement
of Medical Science. NOD was supported by NIH grants HL-38180 and
DK-42030.
REFERENCES
Anant S, MacGinnitie AJ, Davidson NO: Apobec-1, the catalytic subunit of the
mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding
protein. J Biol Chem 270:14762–14767, 1995
Anant S, Martin SA, Yu H, MacGinnitie AJ, Devaney E, Davidson NO: A cytidine
deaminase expressed in the post-infective L3 stage of the filarial nematode,
Brugia pahangi, has a novel RNA-binding activity. Mol Biochem Parasitol 88:105–
114, 1997
Ashkenas J: Gene regulation by mRNA editing. Am J Hum Genet 60:278–283, 1997
Barker JN: The immunopathology of psoriasis. Baillie`res Clin Rheumatol 8:429–
438, 1994
Barker JN: Adhesion molecules in cutaneous inflammation. CIBA Found Symp
189:91–101; 1995
Betts L, Xiang S, Short SA, Wolfenden R, Carter CWJ: Cytidine deaminase. The
2.3 A crystal structure of an enzyme: transition-state analog complex. J Mol
Biol 235:635–656, 1994
Bhattacharya S, Navaratnam N, Morrison JR, Scott J, Taylor WR: Cytosine
nucleoside/nucleotide deaminases and apolipoprotein B mRNA editing. Trends
Biochem Sci 19:105–106, 1994
Bravo R, Celis JE: Up-dated catalogue of HeLa cell proteins: percentages and
characteristics of the major cell polypeptides labeled with a mixture of 16
[14C]-labeled amino acids. Clin Chem 28:766–781, 1982
Calkhoven CF, Bouwman PR, Snippe L, Ab G: Translation start site multiplicity of
the CCAAT/enhancer binding protein alpha mRNA is dictated by a small 59
open reading frame. Nucleic Acids Res 22:5540–5547, 1994
Cappione AJ, French BL, Skuse GR: A potential role for NF1 mRNA editing in
the pathogenesis of NF1 tumors. Am J Hum Genet 60:305–312, 1997
Celis JE, Basse B, Lauridsen JB. Determination of antibody specificity by Western
blotting and immunoprecipitation. In: Celis JE (ed.). Cell Biology. A Laboratory
Handbook, Vol. 2. San Diego: Academic Press, 1994a: pp 305–321
Celis JE, Ratz G, Basse B, Lauridsen JB, Celis A. high-resolution two dimensional
gel electrophoresis of proteins: isoelectric focusing and nonequilibrium pH
gradient electrophoresis (NEPHGE). In: Celis JE (ed.). Cell Biology: a Laboratory
Handbook, Vol. 3. San Diego: Academic Press, 1994b: pp 222–230
Celis JE, Gromov P, Ostergaard M, et al: Human 2-D PAGE databases for proteome
analysis in health and disease: http://biobase.dk/cgi-bin/celis. FEBS Lett
398:129–134, 1996
Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ: Isolation of biologically
active ribonucleic acid from sources enriched in ribonuclease. Biochemistry
18:5294–5299, 1979
Christensen JH, Hansen PK, Lillelund O, Thøgersen HC: Sequence-specific binding
of the N-terminal three-finger fragment of Xenopus transcription factor IIIA
to the internal control region of a 5S RNA gene. FEBS Lett 281:181–184, 1991
Christophers E: Psoriasis: mechanisms and entry points for possible therapeutic
interventions. Australas J Dermatol 37 (Suppl. 1):S4–S6, 1996
Collins JE, Cole CG, Smink LJ, et al: A high-density YAC contig map of human
chromosome 22. Nature 377:367–379, 1995
Descombes P, Schibler U: A liver-enriched transcriptional activator protein, LAP,
and a transcriptional inhibitory protein, LIP, are translated from the same
mRNA. Cell 67:569–579, 1991
Elder JT, Tavakkol A, Klein SB, Zeigler ME, Wicha M, Voorhees JJ: Protooncogene
expression in normal and psoriatic skin. J Invest Dermatol 94:19–25, 1990
Felsenstein J: Phylogenies from molecular sequences: inference and reliability. Annu
Rev Genet 22:521–565, 1988
Fisher GJ, Talwar HS, Baldassare JJ, Henderson PA, Voorhees JJ: Increased
phospholipase C-catalyzed hydrolysis of phosphatidylinositol-4,5-bisphosphate
and 1,2-sn-diacylglycerol content in psoriatic involved compared to uninvolved
and normal epidermis. J Invest Dermatol 95:428–435, 1990
Fisher GJ, Tavakkol A, Leach K, et al: Differential expression of protein kinase C
isoenzymes in normal and psoriatic adult human skin: reduced expression of
protein kinase C-beta II in psoriasis. J Invest Dermatol 101:553–559, 1993
Geballe AP, Morris DR: Initiation codons within 59-leaders of mRNAs as regulators
of translation. Trends Biochem Sci 19:159–164, 1994
Giannoni F, Bonen DK, Funahashi T, Hadjiagapiou C, Burant CF, Davidson
NO: Complementation of apolipoprotein B mRNA editing by human liver
accompanied by secretion of apolipoprotein B48. J Biol Chem 269:5932–
5936, 1994
Gubler U, Hoffman BJ: A simple and very efficient method for generating cDNA
libraries. Gene 25:263–269, 1983
Gupta AK, Fisher GJ, Elder JT, Nickoloff BJ, Voorhees JJ: Sphingosine inhibits
phorbol ester-induced inflammation, ornithine decarboxylase activity, and
activation of protein kinase C in mouse skin. J Invest Dermatol 91:486–491, 1988
Hegemann L, van Bonnekoh B, Rooijen LA, Mahrle G: Anti-proliferative effects
of protein kinase C inhibitors in human keratinocytes. J Dermatol Sci 4:18–
25, 1992a
Hegemann L, van Fruchtmann R, Rooijen LA, Muller-Peddinghaus R, Mahrle G:
The antipsoriatic drug, anthralin, inhibits protein kinase C—implications for
its mechanism of action. Arch Dermatol Res 284:179–183, 1992b
Hochuli E, Dobeli H, Schacher A: New metal chelate adsorbent selective for proteins
and peptides containing neighbouring histidine residues. J Chromatogr 411:177–
184, 1987
Honore´ B, Madsen P: The tetramethylammonium chloride (TMAC) method for
screening cDNA libraries with highly degenerate oligonucleotide probes
obtained by reverse translation of amino acid sequences. Methods Mol Biol
69:139–146, 1997
Horn F, Marks F, Fisher GJ, Marcelo CL, Voorhees JJ: Decreased protein kinase C
activity in psoriatic versus normal epidermis. J Invest Dermatol 88:220–222, 1987
Kozak M: The scanning model for translation: an update. J Cell Biol 108:229–241, 1989
Laemmli UK: Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 227:680–685, 1970
MacGinnitie AJ, Anant S, Davidson NO: Mutagenesis of apobec-1, the catalytic
subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals
VOL. 113, NO. 2 AUGUST 1999 cDNA CLONING AND EXPRESSION OF PHORBOLIN-1 169
distinct domains that mediate cytosine nucleoside deaminase, RNA binding,
and RNA editing activity. J Biol Chem 270:14768–14775, 1995
Madsen P, Rasmussen HH, Leffers H, et al: Molecular cloning, occurrence, and
expression of a novel partially secreted protein ‘psoriasin’ that is highly up-
regulated in psoriatic skin. J Invest Dermatol 97:701–712, 1991
Madsen P, Rasmussen HH, Leffers H, Honore´ B, Celis JE: Molecular cloning and
expression of a novel keratinocyte protein (psoriasis-associated fatty acid-
binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and
that shares similarity to fatty acid-binding proteins. J Invest Dermatol 99:299–
305, 1992
Madsen P, Gromov P, Celis JE: Expression of cDNA clones by coupled in vitro
transcription/translation and transfection into COS-1 cells: protein mapping
in two-dimensional gels. Electrophoresis 16:2258–2261, 1995
Navaratnam N, Bhattacharya S, Fujino T, Patel D, Jarmuz AL, Scott J: Evolutionary
origins of apoB mRNA editing: catalysis by a cytidine deaminase that has
acquired a novel RNA-binding motif at its active site. Cell 81:187–195, 1995
Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of
protein kinase C. Science 258:607–614, 1992
Norris DA, Travers JB, Leung DY: Lymphocyte activation in the pathogenesis of
psoriasis. J Invest Dermatol 109:1–4, 1997
O’Farrell PH: High resolution two-dimensional electrophoresis of proteins. J Biol
Chem 250:4007–4021, 1975
Peltonen J, Karvonen SL, Yla-Outinen H, Hirvonen O, Karvonen J: Lesional
psoriatic epidermis displays reduced neurofibromin immunoreactivity. J Invest
Dermatol 105:664–667, 1995
Rasmussen HH, Celis JE: Evidence for an altered protein kinase C (PKC) signaling
pathway in psoriasis. J Invest Dermatol 101:560–566, 1993
Reynolds K, Zimmer AM, Zimmer A: Regulation of RAR beta 2 mRNA
expression: evidence for an inhibitory peptide encoded in the 59-untranslated
region. J Cell Biol 134:827–835, 1996
Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating
inhibitors. Proc Natl Acad Sci USA 74:5463–5467, 1977
Sharma PM, Bowman M, Madden SL, Rauscher FJ, Sukumar S: RNA editing in
the Wilms’ tumor susceptibility gene, WT1. Genes Dev 8:720–731, 1994
Skuse GR, Cappione AJ, Sowden M, Metheny LJ, Smith HC: The neurofibromatosis
type I messenger RNA undergoes base-modification RNA editing. Nucleic
Acids Res 24:478–485, 1996
Teng B, Burant CF, Davidson NO: Molecular cloning of an apolipoprotein B
messenger RNA editing protein. Science 260:1816–1819, 1993
Tommerup N, Vissing H: Isolation and fine mapping of 16 novel human zinc finger-
encoding cDNAs identify putative candidate genes for developmental and
malignant disorders. Genomics 27:259–264, 1995
Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from
polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc Natl Acad Sci USA 76:4350–4354, 1979
Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L: Psoriasis: a T-cell-mediated
autoimmune disease induced by streptococcal superantigens? Immunol Today
16:145–149, 1995
Rasmussen HH, Van Damme J, Bauw M, Puype M, Gesser B, Celis JE,
Vanderkerckhove J. Protein-electroblotting and microsequencing in establishing
integrated human protein databases. In: Jo¨rnvall H, Ho¨o¨g JO, Gustavsson AM
(eds). Methods in Protein Sequence Analysis. Basel: Birkha¨user, 1991:pp 103–141
Vanderkerckhove J, Rasmussen HH. Internal amino acid sequencing of proteins
recovered from one- or two dimensional gels. In: Celis JE (ed.) Cell Biology.
A Laboratory Handbook, Vol. 3. San Diego: Academic Press, 1994:pp 359–368
Venneker GT, Das PK, van Meinardi MM, Marle J, Veen HA, Bos JD, Asghar
SS: Glycosylphosphatidylinositol (GPI) -anchored membrane proteins are
constitutively down-regulated in psoriatic skin. J Pathol 172:189–197, 1994
Wiedow O, Young JA, Davison MD, Christophers E: Antileukoprotease in psoriatic
scales. J Invest Dermatol 101:305–309, 1993
Wright NA, Camplejohn RS: Psoriasis: Cell proliferation. Edinburgh: Churchill
Livingstone, 1985,
Xie YG, Han FY, Peyrard M, et al: Cloning of a novel, anonymous gene from a
megabase-range YAC and cosmid contig in the neurofibromatosis type 2/
meningioma region on human chromosome 22q12. Hum Mol Genet 2:1361–
1368, 1993
